HK Stock Market Move | IMMUNEONCO-B (01541) rose more than 6%, with a total of $20 million received for the collaboration projects IMM2510 and IMM27M reached with Instil Bio.

IMMUNEONCO-B(01541) rose over 6%, as of the time of writing, up by 6.13% to HKD 6.41, with a trading volume of 3.7406 million Hong Kong dollars. On the news front, on May 7th, IMMUNEONCO announced that it has received the second payment of $5 million as scheduled for its authorization and cooperation with Instil Bio, Inc on IMM2510 and IMM27M, aiming for August 1, 2024. With the smooth and rapid progress of the clinical cooperation development, the total amount received for the project has now reached $20 million. Currently, IMM2510 has completed a dose escalation clinical trial for advanced solid tumors and has shown multiple efficacy signals, including significant efficacy in squamous non-small cell lung cancer patients who have failed PD-1 inhibitor treatment. Additionally, phase II clinical studies combining IMM2510 with chemotherapy for first-line treatment of non-small cell lung cancer patients, and combining IMM2510 with IMM27M for the treatment of advanced solid tumors, have already started enrollment.